SLU-PP-332 is marketed as an "exercise mimetic": a compound that switches on some of the genes a bout of aerobic exercise switches on. It is sold as tablets, capsules and injection vials, often next to research peptides, although it is a small synthetic molecule, not a peptide. The dosing record — every figure in the literature is a mouse dose by injection — is on our SLU-PP-332 dosage page. This page asks the other question: what is known about harm.
The short answer is that no human has ever been studied, and the animal studies were not designed to find harm. What follows is the full census, so the absence can be checked rather than taken on trust.
The record, counted
Searched on 30 September 2026:
| Where a finding would be | Query | Result |
|---|---|---|
| ClinicalTrials.gov (v2 API) | "SLU-PP-332" | 0 studies |
| openFDA adverse-event database (FAERS) | product name "SLU-PP-332" | 0 reports |
| PubMed | "SLU-PP-332" | 10 records |
The ten PubMed records sort into five studies in live mice (2023–2026, one of them mainly about the successor molecule SLU-PP-915), two anti-doping metabolism studies in human liver fractions (2026), one study in cultured human muscle cells (2025), one medicinal-chemistry paper (2026), and one Spanish-language systematic review in Revista Médica de Chile (2026). There is no human dosing study of any kind.
What the mouse studies noticed
The in vivo work comes from the laboratory that designed the compound and its collaborators. It was built to measure metabolism, exercise capacity, kidney ageing and heart failure, so safety observations appear only in passing:
- Poor tolerance of the injections. In the 2024 metabolic-syndrome study, male mice received 50 mg/kg by intraperitoneal injection twice daily. The methods state that the arm in genetically obese ob/ob mice was "shortened to 12 days due to reduced tolerance of twice per day intraperitoneal administration." The paper does not describe what the reduced tolerance looked like.
- Weight loss without eating less. Diet-induced obese mice weighed about 12% less than vehicle-treated mice after 28 days; vehicle mice gained about 5 g of fat against under 0.5 g on the drug, with no significant difference in food intake or lean mass. The authors frame this as the intended effect. It is also an unexplained increase in energy expenditure, and nobody measured body temperature or heart rate while it happened.
- Blood tests. The same paper reports "only relatively minor changes in plasma cholesterol and liver enzyme levels" in lean mice, and falls in total cholesterol, HDL and triglycerides in obese mice. No kidney or blood-count panel is reported.
- Heart. In the 2024 Circulation heart-failure study, mice with surgically induced pressure overload were given 25 mg/kg twice daily; SLU-PP-332 improved ejection fraction and survival and did not change heart wall thickening. The paper states, for the related molecule SLU-PP-915, that it saw no "overt toxicity" over six weeks; it makes no equivalent statement for SLU-PP-332. It also reports that activating these receptors switched off genes for cell division and development in heart muscle cells.
Every one of these studies injected the compound into the abdominal cavity, for no longer than about eight weeks. The two papers we read in full used a vehicle of DMSO and Cremophor in saline — a solvent mix that has effects of its own — and the metabolic study states that its animals were male; neither reports work in females.
What nobody has looked at
No published study of SLU-PP-332 reports any of the following:
- A toxicology programme of the kind a drug needs before first use in people: single- and repeat-dose toxicity in two species, genotoxicity, safety pharmacology (heart rhythm, blood pressure, breathing, nervous system), reproductive or developmental studies.
- Any study designed to compare effects in female animals.
- Any data by mouth. The developers wrote in January 2026 that SLU-PP-332 "lacks oral bioavailability", and moved to a different molecule for oral work. Tablets and capsules are what is sold.
- Heart rate or body temperature during the rise in energy expenditure.
- Interactions with other drugs, although the anti-doping laboratories show it is extensively metabolised by the liver — into 22 metabolites in the UCLA study and 9 in the Cologne study.
Where the human side-effect lists come from
Vendor and forum pages circulate lists of human side effects. None of them traces to any study of SLU-PP-332 in people, because there is none. They are user reports from an unverified product of unknown content, and this page records them as a category of claim, not as evidence. A reader cannot tell from such a report whether the tablet contained SLU-PP-332, how much, or what else.
What regulators and sports bodies have said
FDA's adverse-event database holds no report naming it. The anti-doping world has moved faster than the medical one: the UCLA Olympic Analytical Laboratory states that the World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators, and both it and the Cologne laboratory published detection methods in 2026. The 2026 systematic review in Revista Médica de Chile concludes that "clinical trials are needed to confirm their efficacy and safety in humans."
Reading this record
"No reported side effects" and "no known side effects" are the wrong summaries here. The accurate one is that the compound has never been given to a person under observation, and that the animal studies were short, single-sex, injected and aimed elsewhere. Anyone who has taken it and has symptoms, or is weighing it, should take the question to a doctor and say what the product was and how it was sourced.
The wider pattern — why low report counts for research compounds mean little — is on our peptide side-effects overview. A close cousin in the metabolic research market with a similarly thin record is covered on our 5-amino-1MQ dosage page, and the question of why almost nothing sold as a tablet in this market has had its absorption measured is on our oral peptides page. What the compound is and how it acts is summarised in Peptide Lexicon's SLU-PP-332 entry.
Sources and dates
- ClinicalTrials.gov v2 API, term "SLU-PP-332": 0 studies, 2026-09-30. openFDA drug adverse-event endpoint, medicinal product "SLU-PP-332": no matches, 2026-09-30 (dataset updated 2026-07-30).
- PubMed via NCBI E-utilities, "SLU-PP-332": 10 records, abstracts read 2026-09-30.
- Billon C et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther 2024;388(2):232-240 (PMID 37739806; full text PMC10801787, methods and results read).
- Xu W et al. Novel pan-ERR agonists ameliorate heart failure. Circulation 2024;149(3):227-250 (PMID 37961903; full text PMC10842599, methods and results read).
- Wang XX et al. Am J Pathol 2023;193(12):1969-1987 (PMID 37717940). Billon C et al. J Pharmacol Exp Ther 2026;393(1):103787 (PMID 41421047).
- Avliyakulov NK et al. Drug Test Anal 2026;18(3):439-450 (PMID 41688415). Möller T et al. Rapid Commun Mass Spectrom 2026;40(8):e70039 (PMID 41588687).
- de Souza-Lima J et al. Rev Med Chil 2026;154(2):237-245 (PMID 42024694).
Corrections go to the contact page.